Last reviewed 2026-04-22 · How we verify

CT-P17

CT-P17 is a monoclonal antibody that binds to and inhibits programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and restoring anti-tumor immune responses.

CT-P17 is a monoclonal antibody that binds to and inhibits programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and restoring anti-tumor immune responses. Used for Non-small cell lung cancer, Other solid tumors (under investigation).

At a glance

Mechanism of action

CT-P17 is a PD-L1 checkpoint inhibitor designed to prevent tumor cells from evading the immune system. By blocking the PD-L1/PD-1 interaction, the drug releases the brakes on T-cell mediated immunity, allowing immune cells to recognize and attack cancer cells. This mechanism is similar to other approved PD-L1 inhibitors and is intended to treat various solid tumors.

Approved indications

• Non-small cell lung cancer
• Other solid tumors (under investigation)

Common side effects

• Fatigue
• Immune-related adverse events (pneumonitis, hepatitis, colitis)
• Infusion reactions

Key clinical trials

• To Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis (PHASE3)
• Yuflyma® (Adalimumab), Patient Experience After Switching
• To Compare the Pharmacokinetics and Safety of CT-P17 and Humira in Healthy Subjects (PHASE1)
• A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis (PHASE3)
• A Study to Compare Efficacy and Safety of CT-P17 With Humira in Patients With Active Rheumatoid Arthritis (PHASE3)
• To Compare the Pharmacokinetics and Safety of the Auto-injector and Pre-filled Syringe of CT-P17 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.